Abbott Laboratories (NYSE: ABT) received FDA approval for its Volt PFA System to treat atrial fibrillation (AFib). AFib affects 12 million Americans over 65, with risks of stroke and mortality. The FDA approval was based on the VOLT-AF IDE study results showing safety and effectiveness in two patient groups.

Abbott Laboratories (NYSE: ABT) is a global healthcare leader offering life-changing technologies in diagnostics, medical devices, nutritionals, and branded generic medicines. The company plans to launch the Volt PFA System in the US and expand in the EU. AFib patients may benefit from minimally invasive cardiac ablation procedures when other treatments fail.

Read more at Yahoo Finance: Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment